Earnings Preview: Lineage Cell Therapeutics
Portfolio Pulse from Benzinga Insights
Lineage Cell Therapeutics (LCTX) is set to release its quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-0.04. The company's past performance shows a pattern of beating EPS estimates, which has led to share price increases. However, the stock has been down 18.05% over the last 52-week period.
November 08, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lineage Cell Therapeutics is expected to report an EPS of $-0.04. The company has a history of beating EPS estimates, which could potentially lead to a short-term increase in share price. However, the stock has been down 18.05% over the last year, indicating a bearish sentiment among long-term shareholders.
The company's past performance of beating EPS estimates could potentially lead to a short-term increase in share price. However, the overall bearish trend over the past year could dampen any positive impact. The earnings report will provide more clarity on the company's financial health and future prospects, which will influence investor sentiment and the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100